Eikon Therapeutics, Inc. (EIKN) Stock Price & Analysis

Eikon Therapeutics, Inc. (EIKN) closed at USD 5.87 on Monday, November 9, 2026, down 0.51% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 5.9; the Nov 9, 2026 session ranged USD 5.62–6.04 on volume of 722,194 shares. Market capitalization is $317.95M, with a 52-week range of USD 5.01–17.4 (NMS). Source: Nexqual, retrieved November 10, 2026 at 10:43 UTC.

Also available as compact Markdown for AI agents: nexqual.com/EIKN.md

Key facts (EIKN)

• 1 of 80 tracked superinvestors hold EIKN (13F, Q2 2026): 1 new, 0 added, 0 reduced, 0 unchanged.
• Insider open-market purchases, last ~7 months: 1 Form 4 filing, $1.0M; 0 by opportunistic insiders, 0 by routine insiders.
• Analysts: Buy (mean 2.00 on a 1–5 scale) (7 analysts), mean target USD 24.33 (range 4–32).
• Total return with dividends: 5Y -59.5% vs S&P 500 +72.2%.
• Next earnings: 2026-11-12, EPS estimate USD -1.6, revenue estimate $0K. All companies reporting that day: https://nexqual.com/earnings/2026-11-12
• Dividend: EIKN paid no cash dividend in the last five years.
• Short interest: 15.62% of float (as of 2026-10-15), 9.8 days to cover.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (EIKN)

P/B 0.7x · FCF yield -90.14% · Earnings yield -108.45%

Superinvestors (SEC 13F-HR, Q2 2026) (EIKN)

1 of 80 tracked investors hold EIKN. Each row is the investor's latest 13F; change is vs their prior-quarter share count.

Insider purchases (SEC Form 4, open-market, last ~7 months) (EIKN)

1 purchase, $1.0M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (EIKN)

Consensus Buy (mean 2.00 on a 1–5 scale), 7 analysts; mean target USD 24.33 (low 4, high 32).

Rating changes, last 120 days:

Total return (dividends reinvested) (EIKN)

Dividends (EIKN)

EIKN paid no cash dividend in the last five years.

Short interest (EIKN)

6,370,634 shares sold short, 15.62% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 5,452,560 shares (+16.8%). Days to cover: 9.8 (short shares ÷ average daily volume).

EIKN earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

EIKN recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

EIKN suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 30, 2026.

EIKN company outlook (results filed Aug 13, 2026)

• “Approximately 30 PARPi-naïve, HER2-negative breast cancer patients are expected to be enrolled at each dose level.”
• “Preclinically, Eikon scientists have shown that EIK1006 binds to the ligand binding domain of AR and blocks its nuclear translocation, thereby inhibiting AR transcriptional activity and downstream signaling. • Eikon expects to submit an investigational new drug application (IND) for EIK1006 by the end of 2026.”
• “DRAFT • EIK1004: Presenting initial Phase 1/2 data in patients with advanced solid tumors on Friday, October 23 at ESMO. • EIK1005: Presenting initial Phase 1/2 data in patients with advanced solid tumors on Friday, October 23 at the ESMO Congress 2026. • EIK1006: Expects to submit an IND by the end of 2026.”
• “Eikon expects its current cash, cash equivalents, and marketable securities to fund operations into the second half of 2027.”

Quoted word-for-word from the SEC 8-K results press release.

EIKN analyst estimates and revisions

Key Statistics (as of November 10, 2026 at 10:43 UTC)

Technical Analysis (EIKN)

Nexqual's technical model rates EIKN "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of November 10, 2026 at 10:43 UTC.

Analyst Ratings (EIKN)

Wall Street analysts rate EIKN "Buy" based on 7 analysts, with a mean price target of USD 24.33 (range USD 4–32), per Nexqual as of November 10, 2026 at 10:43 UTC.

Earnings (EIKN)

Recent Earnings History

Source: Nexqual, November 10, 2026 at 10:43 UTC.

Financials & Fundamentals (EIKN)

Source: Nexqual, November 10, 2026 at 10:43 UTC.

Financial Health Score (EIKN)

Nexqual rates Eikon Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of November 10, 2026 at 10:43 UTC.

Ownership (EIKN)

Source: Nexqual, November 10, 2026 at 10:43 UTC.

Leadership (EIKN)

Eikon Therapeutics, Inc. is led by Roger M. Perlmutter, Chairman, President & CEO, per Nexqual as of November 10, 2026 at 10:43 UTC.

Major Backers & Investors (EIKN)

Notable institutional backers of Eikon Therapeutics, Inc. include FMR, LLC, Foresite Capital Management IV, LLC, Fidelity, according to Nexqual as of November 10, 2026 at 10:43 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, November 10, 2026 at 10:43 UTC.

From Eikon Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)

Key Strengths & Strategy (as disclosed to the SEC)

• Our strategy centers around deploying our technology platform, including our proprietary single molecule tracking, or SMT, system, to develop internally-derived novel therapies, while also leveraging the deep expertise of our management team to opportunistically in-license promising assets.
• Our Chief Technical Officer, Russ Berman, has been a key contributor to the creation of our technology platform, consisting of our proprietary SMT system, bespoke automation, data science ML and AI tools, and software engineering capable of processing petabyte-scale datasets.
• Our technology platform is centered around our proprietary SMT system, integrating tools such as custom-engineered super-resolution microscopy, bespoke automation, advanced data science, and software packages capable of processing petabyte-scale datasets.
• Our research strategy leverages internal drug discovery techniques including the use of our proprietary SMT system and our proprietary artificial intelligence, or AI, and machine learning, or ML, algorithms.

Partnerships

• We in-licensed EIK1001 from Seven and Eight Biotherapeutics Corp. pursuant to an Exclusive Collaboration Agreement with Seven and Eight Biotherapeutics Corp. and related entities, collectively known as Seven and Eight, and an Exclusive License and Development Agreement with Seven and Eight and Superb Wisdom Limited, or SW.
• Following completion of Cohort 1A dose escalation, we reached agreement with the FDA on a dose optimization strategy for Part 2 of the trial.

Legal & Regulatory Risks (Item 1A, quoted)

• Our current and future relationships with healthcare providers and physicians and third-party payors may be subject to applicable anti-kickback, fraud and abuse, transparency, health privacy, and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, and diminished profits and future earnings.
• We may attempt to seek approval from the FDA for one or more of our product candidates through the use of the accelerated approval pathway.
• We may in the future seek approval for one or more of our product candidates under the FDA’s accelerated approval pathway.
• We may seek a Breakthrough Therapy or Fast Track designation or priority review voucher for current or future product candidates, but we might not receive such designation, and even if we do, we may not maintain such designation. Such designation may not lead to faster development, regulatory review, or approval, and will not increase the likelihood that the product candidate will receive marketing approval.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 10, 2026 at 10:43 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt